Table 1 Baseline characteristics of cancer patients.

From: Characterisation of gut microbiota in Malaysian cancer patients using V3-V4 region of 16S rRNA gene sequencing

Characteristics

Overall

(N = 53)

Pre-treatment

(N = 13)

During treatment

(N = 40)

p-value

Age

Range

Median (IQR)

Mean (SD)

1–96

13 (4–47.5)

24.92 (26.394)

2–17

6 (3.5–13)

8 (5.4)

1–96

16 (4.3–55.5)

30.4 (28.17)

a0.703

Age groups

≤ 3

4–6

7–12

13–18

19–39

40–59

≥ 60

10 (18.9%)

9 (17.0%)

7 (13.2%)

8 (15.1%)

4 (7.5%)

7 (13.2%)

8 (15.1%)

3 (23.1%)

4 (30.8%)

3 (23.1%)

3 (23.1%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

7 (17.5%)

5 (12,5%)

4 (10.0%)

5 (12.5%)

4 (10.0%)

7 (17.5%)

8 (20.0%)

b0.114

Gender

Male

Female

32 (60.4%)

21 (39.6%)

7 (53.8%)

6 (46.2%)

25 (62.5%)

15 (37.5%)

b0.579

Gastrointestinal symptoms

Asymptomatic

Symptomatic

34 (64.2%)

19 (35.8%)

13 (100.0%)

0 (0.0%)

21 (52.5%)

19 (47.5%)

b,*0.002

Cancer Type

Solid tumour

Uncharacterised solid tumour

Medulloblastoma

Ewing Sarcoma

Osteosarcoma

Germinoma

Angiofibroma

LCH

Haematological malignancies

ALL

AML

Lymphoma

JMML

Uncharacterised leukaemia

16 (30.2%)

3 (5.7%)

2 (3.8%)

2 (3.8%)

2 (3.8%)

1 (1.9%)

1 (1.9%)

17 (32.1%)

6 (11.3%)

1 (1.9%)

1 (1.9%)

1 (1.9%)

1 (7.7%)

2 (15.4%)

1 (7.7%)

1 (7.7%)

0 (0.0%)

1 (7.7%)

1 (7.7%)

5 (38.5%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

1 (7.7%)

15 (37.5%)

1 (2.5%)

1 (2.5%)

1 (2.5%)

2 (5.0%)

0 (0.0%)

0 (0.0%)

12 (30.0%)

6 (15.0%)

1 (2.5%)

1 (2.5%)

0 (0.0%)

b*0.047

Cancer Group

Solid tumour

Haematological malignancies

28 (52.8%)

25 (47.2%)

7 (53.8%)

6 (46.2%)

21 (52.5%)

19 (47.5%)

b0.933

  1. N = Total number of samples; n = number of samples examined; IQR = Interquartile range; SD = Standard deviation; ALL = acute lymphoblastic leukaemia; AML = acute myeloid leukaemia; JMML = juvenile myelomonocytic leukaemia; LCH = Langerhans cell histiocytosis. *The distribution of pre-treatment and during-treatment cancer patients based on their gastrointestinal symptoms was significantly different based on the Chi-square test (p < 0.05). aThe distribution of age across treatment groups was measured with the Kruskal-Wallis test (p > 0.05). bThe distribution of age groups, gender, GI symptoms, cancer type and cancer groups across treatment groups was measured with a Chi-square test (p > 0.05).
Back to article page